Aileens Pharma focuses on the development of medical devices for the treatment and management of inflammatory skin diseases and conditions.

The proprietary technology HAc40 is based on bacterial cell wall fragments derived from the healthy human skin microbiota, conjugated with sodium hyaluronate or other mucopolysaccardes. This approach targets the altered skin microbiota and its interkingdom interactions, supporting the restoration of skin homeostasis while ensuring high efficacy and tolerability.

Flagship products include LimpiAD, indicated for atopic dermatitis and supportive care in radiotherapy-induced dermatitis, and LimpiAL, developed for psoriasis.